Investigational drug · Phase 3
Cagrilintide
Not approved by FDA. In 20 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Type 2 Diabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
20
8 still active
All registered trials
45
Any phase or sponsor naming "Cagrilintide"
First trial start
2022
Nov 1, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cagrilintide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Type 2 Diabetes
- Type 2 Diabetes Mellitus
- Obesity or Overweight
- Hypertension
- Cardiovascular Disease
- Alcohol-related Liver Disease
- Chronic Kidney Disease
- Diabetes Mellitus, Type 2
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · High blood pressure (hypertension) · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Cagrilintide" as an intervention, largest first.
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05669755 · 7,101 participants · Start Mar 1, 2023 · Primary completion Sep 1, 2027
Drug: Cagrilintide; Semaglutide and 1 more · For: Cardiovascular Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 633 sites in all
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05567796 · 3,400 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 30, 2024
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 256 sites in all
- A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06065540 · 2,734 participants · Start Sep 27, 2023 · Primary completion Nov 19, 2025
Drug: Cagrilintide; Semaglutide and 2 more · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Pelham, Alabama; Phoenix, Arizona · 405 sites in all
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07564414 · 2,500 participants (planned) · Start May 21, 2026 · Primary completion Feb 23, 2028
Drug: Cagrisema; Semaglutide · For: Obesity; Type 2 Diabetes
Sites: Birmingham, Alabama; Pelham, Alabama; Gilbert, Arizona · 303 sites in all
- A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07919405 · 1,408 participants (planned) · Start Nov 11, 2026 · Primary completion Jun 1, 2028
Drug: CagriSema; Semaglutide and 2 more · For: Hypertension; Obesity
Sites: Concord, California; Costa Mesa, California; Fullerton, California · 212 sites in all
- A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05394519 · 1,200 participants · Start Feb 1, 2023 · Primary completion Jan 28, 2025
Drug: Cagrilintide; Semaglutide and 2 more · For: Overweight; Obesity; Type 2 Diabetes Mellitus
Sites: Concord, California; Escondido, California; Fullerton, California · 179 sites in all
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06221969 · 1,024 participants · Start Jan 16, 2024 · Primary completion Mar 4, 2026
Drug: Cagrilintide; Semaglutide and 1 more · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 197 sites in all
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06534411 · 1,023 participants · Start Nov 5, 2024 · Primary completion Jun 2, 2026
Drug: Cagrilintide; Semaglutide and 1 more · For: Diabetes Mellitus, Type 2
Sites: Pelham, Alabama; Phoenix, Arizona; Tucson, Arizona · 163 sites in all
- A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06131437 · 809 participants · Start Nov 27, 2023 · Primary completion Dec 8, 2025
Drug: Cagrilintide; Semaglutide and 1 more · For: Obesity
Sites: Birmingham, Alabama; Montgomery, Alabama; Costa Mesa, California · 46 sites in all
- A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06131372 · 626 participants · Start Apr 1, 2024 · Primary completion Sep 24, 2025
Drug: Cagrilintide; Semaglutide and 1 more · For: Chronic Kidney Disease; Type 2 Diabetes; Obesity
Sites: Concord, California; Fresno, California; Palm Springs, California · 129 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet MHA, Nardone M, Rensen PCN, et al. · Lancet 2026
- Highly Efficient Iodine-Mediated On-Resin Disulfide Cyclization of Cagrilintide Under Sub-Stoichiometric Conditions.
Patael S, Msallam M, Isaak A, et al. · J Pept Sci 2026
- Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.
Wharton S, Broholm C, Horn D, et al. · Lancet Diabetes Endocrinol 2026
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Panou T, Gouveri E, Popovic DS, et al. · Diabetes Ther 2026
- Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Sanchez-Navarro MJ, Zhang C, Schmidt HD, et al. · Physiol Behav 2026
- Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.
Petersen LM, Knop FK, le Roux CW, et al. · Mol Metab 2026
Also in development for Obesity
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.